Loren Data's SAM Daily™

SAMDAILY.US - ISSUE OF AUGUST 11, 2022 SAM #7559
SOLICITATION NOTICE

66 -- QIAGEN� EZ2� Connect for the Human Leukocyte Antigen (HLA) Lab

Notice Date

8/9/2022 3:49:47 PM
 

Notice Type

Presolicitation
 

NAICS

334516 — Analytical Laboratory Instrument Manufacturing
 

Contracting Office

NATIONAL INSTITUTES OF HEALTH - CC BETHESDA MD 20892 USA
 

ZIP Code

20892
 

Solicitation Number

22-005511
 

Response Due

8/19/2022 9:00:00 AM
 

Point of Contact

Malinda Dehner, Phone: 301-594-6320, Kerry-Ann Chisholm, Phone: 3014969351
 

E-Mail Address

dehnerm@cc.nih.gov, kerry-ann.chisholm@nih.gov
(dehnerm@cc.nih.gov, kerry-ann.chisholm@nih.gov)
 

Description

The National Institutes of Health (NIH) intends to award a fixed priced purchase order on a sole source basis to QIAGEN LLC, Germantown, MD� 20874-1415 to procure the QIAGEN� EZ2� Connect.� This instrument will be used by the NIH, Human Leukocyte Antigen (HLA) Lab of the Department of Transfusion Medicine to isolate DNA from numerous sample types.� The isolated DNA is used to obtain HLA typing results for the numerous transplant protocols supported by the laboratory.� The new instrument will replace one of the existing QIAGEN� EZ1� Advanced X instruments in the lab that was purchased in 2010. Qiagen is the sole manufacturer and registered trademark holder of QIAGEN� EZ2� Connect system.� The HLA lab currently uses Qiagen reagents for DNA isolation from numerous sample types.� The HLA Lab requires this specific instrument for compatibility with the existing instrumentation in place for the earlier model of this instrument.. Integration of the new instrument into the current workflow of the lab will provide a seamless transition with the compatible instrumentation. This acquisition is being conducted under the authority of the FAR Subpart 13.106-1(b)(i), Contracting officers may solicit from one source if the contracting officer determines that the circumstances of the contract action deem only one source reasonably available. Interested concerns capable of providing the same or similar products or services as described in this notice may submit a capability statement outlining their capabilities. Capability Statements must be received within the time set forth in this synopsis to be considered by the Government. A determination to compete this proposed contract based on responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. The total dollar value of this purchase order shall not exceed the SAT at $250,000.00. Each response should include the following Business Information: a. DUNS. b. Company Name, address, POC, Phone and Email address c. Current GSA Schedules or NAICS codes appropriate to this Award. d. Type of Company (i.e., small business, 8(a), woman owned, hubZone, veteran owned, etc.) as validated in System For Award Management (SAM). All offerors must register on the SAM located at http://www.sam.gov/portal/SAM/#1 e. Capability Statement Comments to this announcement may be submitted to the Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, electronically to the attention of Malinda Dehner, Contract Specialist, dehnerm@cc.nih.gov by the due date and time marked in this notice
 

Web Link

SAM.gov Permalink
(https://sam.gov/opp/cfe9ee78901d4614800139fa2a7571e8/view)
 

Place of Performance

Address: Bethesda, MD 20814, USA

Zip Code: 20814

Country: USA
 

Record

SN06420013-F 20220811/220809230122 (samdaily.us)
 

Source

SAM.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's SAM Daily Index Page |